TrialThe Lancet. Oncology2013

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Robert J Motzer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.